Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of

acute decompensated heart failure Acute decompensated heart failure (ADHF) is a sudden worsening of the signs and symptoms of heart failure, which typically includes difficulty breathing (dyspnea), edema, leg or feet swelling, and Fatigue (medical), fatigue. ADHF is a common and ...

. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by

Bristol-Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

. It is a nitroxyl donor. Cimlanod is a

prodrug A prodrug is a medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be used to improve how the drug ...

of CXL-1020. A preliminary study showed efficacy in patients with class III and IV heart failure. A phase II clinical trial was completed in 2016.

References

Experimental drugs Furans Sulfonamides {{cardiovascular-drug-stub